Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Test Your Knowledge Previous | All Articles This Week | Next
This article originally posted 19 January, 2012 and appeared in  MedicationType 2 DiabetesIssue 609

Test Your Knowledge Question #609: A randomized trial compared twice-daily insulin aspart...

A randomized trial compared twice-daily insulin aspart 70/30 (BIAsp 30) with once-daily insulin glargine in patients with type 2 diabetes suboptimally controlled on basal insulin and oral therapy. The patients in the insulin aspart 70/30 arm had...

Advertisement
A. Less hypoglycemia
B. More weight gain
C. Greater HbA1c reduction

D. Greater fasting plasma glucose reduction

E. Lower insulin requirements

Click here for the correct answer.

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 19 January, 2012 and appeared in  MedicationType 2 DiabetesIssue 609

Past five issues: Issue 744 | Diabetes Clinical Mastery Series Issue 203 | Issue 743 | Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
During Prolonged Low-Intensity Exercise, Caffeine Alters Blood Glucose
Posted August 15, 2014
SGLT2 Inhibitor Empagliflozin Wins FDA OK
Posted August 08, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
HbA1c Increases with Age
Posted August 01, 2014
New Way to Regenerate Beta Cells in Type 1 Diabetes Patients
Posted August 08, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
When Afrezza is available, will you prescribe it immediately or wait until it has been on the market for a while?
CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology



Search Articles On Diabetes In Control